Most people know cetirizine as a hay fever tablet. What is far less well known is that cetirizine also blocks a receptor called DP2 — the same receptor through which prostaglandin D2 (PGD2) suppresses hair follicle growth in the scalp. Applied topically at 1%, cetirizine targets this pathway directly, at the follicle level, without affecting hormones, blood pressure, or any of the mechanisms addressed by other hair loss treatments. It is a genuinely different approach — and a compelling one to add to an existing protocol.
PGD2 is elevated threefold in balding scalp and directly inhibits follicular growth — independently of DHT. Topical cetirizine is currently the most accessible, evidence-supported way to block this pathway.
Why does PGD2 cause hair loss?
Research published in Science Translational Medicine in 2012 found that prostaglandin D2 (PGD2) is significantly elevated — approximately three times higher — in balding areas of the scalp compared to non-balding areas in the same person. PGD2 acts through the DP2 receptor on hair follicles to shorten the active growth phase (anagen), pushing follicles into regression earlier and earlier with each cycle. Over time, this progressively miniaturises the follicle — producing the finer, shorter hairs and eventual thinning characteristic of androgenetic alopecia.
Critically, this pathway operates independently of DHT. That means even patients who are already on a 5-alpha reductase inhibitor (like dutasteride or finasteride) — which blocks DHT — may still have active PGD2-mediated hair loss continuing unchecked. Cetirizine addresses this second driver directly.
How does topical cetirizine work?
By applying a 1% cetirizine solution directly to the scalp, the drug reaches the follicular microenvironment in high local concentration and occupies the DP2 receptors that PGD2 would otherwise activate. With DP2 blocked, PGD2's hair-suppressive signal is interrupted — allowing follicles to remain in the growth phase longer, gradually reversing the miniaturisation process, and producing denser, thicker hair over time.
Topical delivery is preferred over oral because it delivers far higher drug concentrations at the scalp — exactly where it's needed — while minimising systemic absorption. This maximises the therapeutic effect and minimises side effects.
What does the evidence show?
A randomised, double-blind, placebo-controlled clinical trial evaluated 1% topical cetirizine applied once daily for six months in patients with androgenetic alopecia. The results were significant:
- Statistically significant increase in hair density (hairs per cm²) compared to placebo
- Significant improvement in mean hair shaft diameter — reflecting reversal of miniaturisation
- Outcomes broadly comparable to topical minoxidil in the same trial
- Good tolerability — no significant side effects leading to discontinuation
Hair shaft diameter is a particularly meaningful endpoint — it directly measures whether miniaturised follicles are recovering, not just whether existing hairs are being retained.
Treatment details
Formulation
1% Topical Solution
Compounded at 1% concentration — the formulation used in clinical trials. Applied directly to the affected scalp using a dropper or pump, once daily.
Dose
1 mL once daily
Applied to dry scalp, ideally in the evening. Part the hair to expose the scalp, apply along the partings, and massage gently. Do not rinse for at least 4 hours.
First results
4–6 months
Reduced shedding is often noticed by months 2–4. Visible improvements in density and thickness typically appear from months 4–6 onward in responders.
Commitment
Ongoing
Like all hair loss pharmacotherapy, cetirizine treats the condition rather than curing it. Stopping treatment allows PGD2 suppression to return and gains are gradually lost.
What to expect — month by month
Months 1–2
No visible change yet — changes are occurring at the follicular level. A mild initial shedding increase is normal and usually self-resolves within 6–8 weeks. This reflects follicles re-entering the growth cycle and is a positive sign, not a reason to stop.
Months 2–4
Daily shedding rate typically stabilises. Hair shafts begin to thicken as follicles that were miniaturising start to reverse. Improvement is happening but not yet visually obvious.
Months 4–6
Most responders begin to notice visible improvements — increased density, less scalp show-through, and thicker hair texture. Trichoscopic assessment at 6 months shows objective changes in hair density and shaft diameter.
6–12 months and beyond
Benefit continues to accumulate through the first year. Maximum improvement is typically reached between 6 and 12 months. Daily treatment continues to maintain results.
Who is cetirizine best suited for?
Topical cetirizine is most useful as part of a multi-pathway hair loss protocol. It is particularly well suited for:
- Patients already on dutasteride or finasteride who want to address the PGD2 pathway as well
- Patients who cannot tolerate 5-alpha reductase inhibitors and are looking for a non-hormonal alternative
- Patients with early-to-moderate AGA where viable follicles remain
- Those seeking a non-hormonal option — cetirizine has no effect on testosterone, DHT, or PSA
- Patients with concomitant allergies (cetirizine addresses both simultaneously)
How it fits with other treatments
Because cetirizine works on a completely different pathway to every other available hair loss treatment, it adds genuinely new therapeutic value rather than duplicating what existing agents already do:
- With dutasteride or finasteride: 5-ARIs block DHT. Cetirizine blocks PGD2. Together they address two of the three main pathophysiological drivers of AGA simultaneously — the most mechanistically complete combination currently accessible.
- With minoxidil: Minoxidil promotes blood flow and anagen entry. Cetirizine removes the PGD2 inhibitory signal. Complementary, non-overlapping actions.
- With LP-PRP: PRP delivers growth factors to support follicular recovery. Cetirizine ensures the PGD2 brake is released so follicles can respond.
Side effects
Cetirizine is one of the safest, best-tolerated medications available. At the topical dose used for hair loss, systemic absorption is substantially lower than a standard oral dose. Side effects to be aware of include:
- Local scalp dryness or mild irritation: Possible with any topical solution; usually mild and transient
- Mild drowsiness: Rare at topical concentrations; applying in the evening further reduces this risk
- Initial shedding: Normal in the first 4–8 weeks — the same phenomenon seen with minoxidil
Importantly, cetirizine has no effect on PSA, testosterone, or DHT — there are no hormonal implications, no reproductive counselling requirements, and no known interactions with finasteride, dutasteride, or minoxidil.
Availability and prescribing
Topical cetirizine is not available as a commercially manufactured product in Australia. It is prepared by a compounding pharmacy pursuant to a prescription from a registered medical practitioner. Its use for androgenetic alopecia is off-label — the TGA has not assessed or approved cetirizine for this indication — but off-label prescribing is legally and ethically appropriate when supported by evidence and conducted within a genuine therapeutic relationship with full informed consent.
A deeper review of the clinical evidence, the full biology of the PGD2 pathway, and a detailed prescribing reference can be found in the linked research article below.